An NCI-designated Comprehensive Cancer Center
Paul Koller bio image

Paul Koller, M.D.

Clinical Expertise
Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Clinical Teams

“City of Hope is one of the best places in the world to treat patients with leukemia.”

The product of a medical family (Mom’s a nurse; Dad was a renowned hematologist), Paul Koller, M.D., proudly continues the family tradition. “My father loved what he did,” he says, “and I saw how much joy he got from being a doctor and how big of an impact he got to have on his patients, and I wanted to be able to impact others the same way he did.”
Dr. Koller received his medical degree from University of Texas Houston and continued his training at Baylor College of Medicine Affiliated Hospitals in Houston and MD Anderson Cancer Center.
Dr. Koller, board certified in hematology and oncology, focuses his research on understanding why some leukemia treatments work better than others. He is excited to join City of Hope “because of the tradition of patient care excellence that I am eager to join,” he says. 


City of Hope Comprehensive Cancer Center, 1500 East Duarte Road

Duarte, CA 91010

  • Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Bottecelli Koller P, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M.  Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica. 2019 May 23;. doi: 10.3324/haematol.2018.205534. [Epub ahead of print] PubMed PMID: 31123034. 
  • Li H, Li CW, Li X, Ding Q, Guo L, Liu S, Liu C, Lai CC, Hsu JM, Dong Q, Xia W, Hsu JL, Yamaguchi H, Du Y, Lai YJ, Sun X, Koller PB, Ye Q, Hung MC.  HYPERLINK MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1. Gastroenterology. 2019 May;156(6):1849-1861.e13. doi: 10.1053/j.gastro.2019.01.252. Epub 2019 Jan 31. PubMed PMID: 30711629. 
  • Koller PB, Kantarjian HM, et al. Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship. Cancer. 2017 Feb 15;123(4):609-616. PMID: 27763690.
  • Kuo DC, Bilal S, Koller P. Asymmetric Weakness and West Nile Virus Infection. J Emerg Med. 2015 Sep;49(3):274-6. PMID: 26095222.
  • Anaya DA, Cormier JN, Xing Y, Koller P, Gaido L, Hadfield D, Chemali R, Feig BW. Development and validation of a novel stratification tool for identifying cancer patients at increased risk of surgical site infection. Ann Surg. 2012 Jan;255(1):134-9. PMID: 22143206.


  • Koller PB, et al. “Association of the GATA3 rs3824662A allele with clinical outcomes in adult patients with adult B-ALL.” Poster ASCO annual meeting. 6/3/2019.
  • Koller PB, Jain N, Zhang H, Roberts K, Qian M, Yang W, Jabbour E, Kantarjian H, Mullighan C, Yang JJ, Konopleva M. “GATA3 rs3824662A allele is overrepresented in adult patients with Ph-like ALL, especially in patients with CRLF2 abnormalities” TxSCO Conference, September 2018.
  • Koller PB, Sasaki K, Ravandi F, Garcia-Manero G, O'Brien S, Cortes JE, Kadia T, Borthakur G, Pemmaraju N, Daver N, Chahoud J, Pike A, Brandt M, Pierce S, Kantarjian HM, Jabbour E. "Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase Il Clinical Trial" ASH, December 2015.
  • Koller PB, Sheikh R, Tan M. "What the Nose Knows" Poster presented at the: 2014 Southern Society of General Internal Medicine; New Orleans, LA. February 2014.
  • Koller PB, Kantarjian H, Koller CA, Jabbour E, O'Brien S, Verstovsek St Borthakur G, Estrov Z, Quintas-Cardama A, Cortes J. "Development of CML in Survivors from previous cancers: A Tale of Dual Survivorship?" 6th Biennial Cancer Survivorship Research Conference: June 2012: Accepted.
  • Koller PB, Kantarjian H, Koller CA, Jabbour E, O'Brien St Verstovsek S, Borthakur G, Estrov Z, Quintas-Cardama A, Cortes J. "Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies." ASH December 2011.
  • Koller P, Logan N, Hamill R, Mehendiratta V, Musher D. "Commercially Available Probiotics." IDSA. Toronto, Ontario, Canada. October 2006.
In The News